Intranasal PH80 Spray for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder (PH80-PMD)
A Phase 3 Study of the Use of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder
Sponsor: Pherin Pharmaceuticals, Inc.
This PHASE3 trial investigates Premenstrual Dysphoric Disorder and is currently ongoing. Pherin Pharmaceuticals, Inc. leads this study, which shows 7 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE3
-
Feb 2018 — Jun 2018 [monthly]
Unknown Status PHASE3
Status: Not Yet Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Feb 2017 — Feb 2018 [monthly]
Not Yet Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE3
First recorded
Mar 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pherin Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .